Antiproliferative compounds and bispecific antibody against BCMA and CD3 for combined use
AssigneeCelgene Corporation
InventorsDaniel W. Pierce, Lilly L. Wong
Life of this patent
Estimating the term…
Abstract
Provided herein is are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof and a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3ε (CD3) provided herein, in treating, preventing or managing multiple myeloma.
Claims20
A method of treating multiple myeloma comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula 1
- or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof;
- in combination with a bispecific antibody comprising a first binding part specifically binding to human B cell maturation antigen (BCMA) and a second binding part specifically binding to human CD3ε (CD3), characterized in that said first binding part comprises a VH region comprising a CDR1H region of SEQ ID NO:21, a CDR2H region of SEQ ID NO:22 and a CDR3H region of SEQ ID NO:17 and a VL region comprising a CDR3L region of SEQ ID NO:20 and a CDR1L and CDR2L region combination selected from the group of
- i) CDR1L region of SEQ ID NO:23 and CDR2L region of SEQ ID NO:24,
- ii) CDR1L region of SEQ ID NO:25 and CDR2L region of SEQ ID NO:26, or
- iii) CDR1L region of SEQ ID NO:27 and CDR2L region of SEQ ID NO:28.
A method of treating multiple myeloma comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula 2
- or a tautomer, isotopolog, or pharmaceutically acceptable salt thereof;
- in combination with a bispecific antibody comprising a first binding part specifically binding to human B cell maturation antigen (BCMA) and a second binding part specifically binding to human CD3ε (CD3), characterized in that said first binding part comprises a VH region comprising a CDR1H region of SEQ ID NO:21, a CDR2H region of SEQ ID NO:22 and a CDR3H region of SEQ ID NO:17 and a VL region comprising a CDR3L region of SEQ ID NO:20 and a CDR1L and CDR2L region combination selected from the group of
- i) CDR1L region of SEQ ID NO:23 and CDR2L region of SEQ ID NO:24,
- ii) CDR1L region of SEQ ID NO:25 and CDR2L region of SEQ ID NO:26, or
- iii) CDR1L region of SEQ ID NO:27 and CDR2L region of SEQ ID NO:28.
Dependencies are inferred from the claim text.